Pancreatitis or inflammation of the pancreas comes in both acute and chronic forms and has long been appreciated as a risk factor for developing pancreatic cancer. While common and in […]
Daraxonrasib, a game changer for pancreatic cancer patients
The wait is over. On Sunday May 31st 2026, Brian M Wolpin MD, MPH, the Director of the Hale Family Center for Pancreatic Cancer Research at Dana Farber Cancer Institute, […]
Innovative Glycoengineering Strategy Could Reveal New Biomarkers for Pancreatic Cancer
While the 5-year survival rate for pancreatic cancer has increased over the last decade to 13%, it continues to be one of the toughest cancers to diagnose and treat. One […]
Join our 18-Day Challenge: 120 New Monthly Donors by June 18th!
Last year’s NIH funding disruptions reminded us how fragile scientific progress can be, but our commitment remains unchanged: patients and families cannot afford for hope or progress to pause. Stories […]
FDA Expands Access to Daraxonrasib: What Patients Need to Know
The FDA has granted permission for Revolution Medicines to provide access to its investigational RAS inhibitor, daraxonrasib, through an Expanded Access Program (EAP) for certain patients with metastatic pancreatic ductal […]
The Promise of Personalized Pancreatic Cancer Vaccines
From April 17-22, 2026, the American Association for Cancer Research (AACR) held their annual meeting in San Diego, CA. The AACR Annual Meeting brings together clinicians, researchers, and health-care professionals […]
